, Lancet Lond Engl, vol.366, pp.665-675, 2005.
Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, vol.99, pp.1915-1942, 2014. ,
Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors, Eur J Endocrinol, vol.175, pp.1-34, 2016. ,
Brown fat imaging with 18 F-6-fluorodopamine PET/CT, 18 F-FDG PET/CT, and 123 I-MIBG SPECT: a study of patients being evaluated for pheochromocytoma, J Nucl Med, vol.48, pp.1077-1083, 2007. ,
Phaeochromocytomas presenting as acute crises after beta blockade therapy, Clin Endocrinol (Oxf), vol.65, pp.186-190, 2006. ,
Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features, Endocrine, vol.45, pp.469-478, 2014. ,
, , p.123
, I-metaiodobenzylguanidine: a limitation to developing cardiac innervation imaging in clinical practice?, Eur Rev Med Pharmacol Sci, vol.17, pp.1326-1333, 2013.
18 F-fluorodihydroxyphenylalanine PET/CT in pheochromocytoma and paraganglioma: relation to genotype and amino acid transport system L, Eur J Nucl Med Mol Imaging, vol.44, pp.812-821, 2017. ,
Clinical value of 18 Ffluorodihydroxyphenylalanine positron emission tomography/computed tomography ( 18 F-DOPA PET/CT) for detecting pheochromocytoma, Eur J Nucl Med Mol Imaging, vol.37, pp.484-493, 2010. ,
Quantitative analysis of normal and pathologic adrenal glands with 18 F-FDOPA PET/CT: focus on pheochromocytomas, Nucl Med Commun, vol.38, pp.771-779, 2017. ,
18 F-DOPA PET/CT in the evaluation of hereditary SDH-deficiency paraganglioma-pheochromocytoma syndromes, Clin Nucl Med, vol.39, pp.53-58, 2014. ,
Quantitative 18 F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype, Eur J Nucl Med Mol Imaging, vol.45, pp.278-282, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01876274